Sarki A Abdulkadir

Title: Innovations of Sarki A Abdulkadir

Introduction

Sarki A Abdulkadir is a notable inventor based in Lombard, IL (US). He has made significant contributions to the field of therapeutics, particularly in the development of compounds that target cancer-related proteins. With a total of five patents to his name, Abdulkadir's work is paving the way for innovative treatments in oncology.

Latest Patents

Among his latest patents, Abdulkadir has developed substituted heterocycles as c-MYC targeting agents. These compounds, which include substituted pyrazoles, substituted pyrimidines, and substituted triazoles, are designed to inhibit c-MYC, a protein implicated in cancer and cell proliferative disorders. Another significant patent involves proteolysis-targeting chimeric molecules (PROTACs) that induce the degradation of c-MYC protein. These PROTACs consist of a targeting moiety that binds to c-MYC and is linked to another moiety that binds to an E3 ubiquitin ligase, showcasing a novel approach to cancer treatment.

Career Highlights

Sarki A Abdulkadir is affiliated with Northwestern University, where he continues to advance his research and innovation in the field of cancer therapeutics. His work is characterized by a strong focus on developing targeted therapies that can effectively combat cancer at the molecular level.

Collaborations

Abdulkadir collaborates with esteemed colleagues such as Gary E Schiltz and Huiying Han, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Sarki A Abdulkadir's contributions to the field of cancer therapeutics through his innovative patents highlight his role as a leading inventor. His work not only advances scientific knowledge but also holds the potential to improve treatment options for patients battling cancer.